Successful Extension of Nucleic Acid Aptamer Pharmacokinetics in Joint Research by Ajinomoto Co., Inc. and RIBOMIC Inc.

Ajinomoto Co., Inc. to Sell its Entire Equity Stake in Ajinomoto Althea, a US-based Aseptic Fill/Finish CDMO

Ajinomoto Bio-Pharma Services Awarded CDMO Leadership Awards

Leading Global CDMO Ajinomoto Bio-Pharma Services Joins CMAC as New Translation to Industry Collaborator

Ajinomoto Bio-Pharma Services Announces the Approval of the 32nd Drug Product at their San Diego Sterile Fill Finish Site

Ajinomoto Bio-Pharma Services Garners Six 'CDMO Leadership Awards,' Further Establishing Its Industry Excellence

Notice Regarding Joint Research Agreement with RIBOMIC Inc.

Ajinomoto Bio-Pharma Services Announces Leadership Changes at US Facility

Ajinomoto Bio-Pharma Services Receives FDA Approval for High Potency Fill Line

Ajinomoto Bio-Pharma Services Awarded Three ‘CDMO Leadership Awards’

Ajinomoto Bio-Pharma Services Successfully Develops Highly Functional Ancestral RNA Ligase

Ajinomoto and Exelixis Enter Into a License Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer

Ajinomoto Bio-Pharma Services Awarded Two ‘CMO Leadership Awards’

Tony O’Neill Joins Ajinomoto Bio-Pharma Services’ Leadership Team as Vice President of Compliance

Ajinomoto Bio-Pharma Services Expands Fill Finish Capacity with New Multi-Purpose Fill Suite

Ajinomoto Bio-Pharma Services Expands Manufacturing Agreement with AstraZeneca to Include Drug Product Manufacturing

Ajinomoto Co., Inc. and Bright Peak Therapeutics Inc. Enter into a Research Collaboration and License Agreement to Create Novel Immunocytokines

Ajinomoto Bio-Pharma Services and Humanigen Expand Manufacturing Agreement to Support Fill Finish for Investigational COVID-19 Therapeutic, Lenzilumab, Nearing Completion of Phase 3 Study

Ajinomoto Bio-Pharma Services and Revance Therapeutics Announce Manufacturing Agreement for Supply of DaxibotulinumtoxinA for Injection

First Commercial Drug Manufactured via Ajinomoto Bio-Pharma Services’ AJIPHASE Technology Receives FDA Approval

Ajinomoto Bio-Pharma Services and DNDi Partner to Develop Critical Immunomodulator for Cutaneous Leishmaniasis Therapeutic

Ajinomoto Bio-Pharma Services Expands Small Molecule Manufacturing Capabilities at its India Facility

Ajinomoto Bio-Pharma Services Introduces AJILITY Fast Track Platform for Drug Product Manufacturing

Ajinomoto Bio-Pharma Services Completes Acquisition of Granules OmniChem Joint Venture in India

Ajinomoto Bio-Pharma Services Signs Manufacturing Agreement with Humanigen for Lenzilumab, Currently in FDA-Approved Phase III Study for COVID-19

Ajinomoto Bio-Pharma Services Announces Manufacturing Partnership with CytoDyn for Drug Product Used in COVID-19 Clinical Trials

Trio Pharmaceuticals, Inc. and Ajinomoto Bio-Pharma Services Enter into a Development Collaboration for a Novel Antibody Therapeutic

Ajinomoto Bio-Pharma Services Announces Formation of External Advisory Board

Ajinomoto Bio-Pharma Services Acquires Remaining Interest in Granules OmniChem Joint Venture in India

GeneDesign Joins Ajinomoto Bio-Pharma Services and Opens Oligonucleotide API Development Center

Jean-Baptiste Agnus Joins Ajinomoto Bio-Pharma Services’ Global Leadership Team as Vice President of Sales and Marketing

Ajinomoto Bio-Pharma Services Announces Capital Expansion to Fuel Growth

Ajinomoto and XL-protein forge Strategic Alliance to develop PASylated therapeutics applying the Corynex® platform

Ajinomoto Bio-Pharma Services Introduces AJICAP Bioconjugation Technology for ADC Manufacturing

Precision NanoSystems Announces Manufacturing Collaboration Agreement with Ajinomoto Bio-Pharma Services for GMP Manufacturing of High Quality Nanomedicines

Ajinomoto Althea and OmniChem Combine to Form Ajinomoto Bio-Pharma Services, Reflecting a Collective Range of Services Offered to the Bio-Pharma Industry

Ajinomoto Althea, Inc. Announces Additions to Management Team as it transforms into a global CDMO

The Government of Flanders recently agreed to participate in Ajinomoto OmniChem’s investments into new and innovative technologies.

On the 22nd September 2017 Granules OmniChem Limited (GOC) received the Establishment Inspection Report (EIR) from the US-FDA

Louvain-la-Neuve: New address from 01/10/2017

Ajinomoto Althea, Inc. Opens Manufacturing Suites in New High Potency and Antibody Drug Conjugate Commercial Facility

Ajinomoto Althea, Inc. Announces New Aseptic Fill Finish Line

CEO J. David Enloe Awarded 'Most Admired CEO'

Ajinomoto OmniChem Launches Flow Chemistry for API Commercial Manufacturing

Ajinomoto OmniChem Launches Flow Chemistry for API Commercial Manufacturing

Ajinomoto Group Acquires All Shares of GeneDesign, a Nucleic Acid Drug CDMO, to Accelerate Expansion of the Contract Business for Oligonucleotides.

Biologics candidate manufactured using Ajinomoto Co., Inc.’s CORYNEX® Protein Expression System enters clinical trials for the first time

Ajinomoto Althea, Inc. Announces Issuance of New US Patent for Manufacturing of Crystal Monoclonal Antibodies

Ajinomoto Althea, Inc. Expands Its Capacity of Fill Finish Manufacturing with Addition of Second Shift

Ajinomoto Althea, Inc. Launches Process and Analytical Development Services for Antibody Drug Conjugates (ADCs) Therapeutics

Ajinomoto Althea, Inc. Expands Manufacturing Capabilities to ADC Fill Finish and Bioconjugation

Ajinomoto Althea, Inc. Awarded CA Tax Credit

Ajinomoto Althea, Inc. Receives European GMP Certification for Commercial Aseptic Filling and Testing

Althea’s New Drug Formulation Technology Gains Attention from Two More Top Pharmaceutical Companies

Ajinomoto Althea, Inc. Receives European GMP Certification

Ajinomoto Althea Inc. Now Offering A Novel Protein Production Platform: Corynex®

Ajinomoto Althea Inc. Appoints J. David Enloe as President and Chief Executive Officer

Ajinomoto Althea, Inc. Selected as a Finalist in 26th Annual CONNECT Most Innovative New Product Awards

Ajinomoto Co., Inc. Completes Acquisition of Althea Technologies, Inc

Ajinomoto Co., Inc. Agrees to Acquire Althea Technologies, Inc.

Althea Technologies & Profectus Biosciences Sign Manufacturing Agreement for Plasmid DNA Production

Pfenex Inc. Awards Althea Technologies a Contract for cGMP Manufacturing of Circumsporozoite Protein from Plasmodium falciparum, a Key Malaria Antigen

Althea Technologies Announces Expanded Roles for Key Executives